Compounds > bexarotene

Page last updated: 2024-08-25

bexarotene and Psoriasis

bexarotene has been researched along with Psoriasis in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (83.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
An, Q; Du, G; Hao, Y; Li, W; Lu, Y; Ren, L; Wang, J; Yang, D; Yang, H; Yang, Y; Yu, M; Zhang, S; Zhang, Y	1
Franssen, ME; Smit, JV; Van De Kerkhof, PC; Van Erp, PE	1
Boezeman, JB; de Jong, EM; Otero, ME; Smit, JV; van de Kerkhof, PC; van Hooijdonk, CA	1
de Jong, EM; De Weert, J; Franssen, ME; Lambert, J; Roseeuw, DI; Smit, JV; Stevens, VJ; van De Kerkhof, PC; Yocum, RC	1
Christiansen, L; Dombrovskiy, V; Gottlieb, AB; Magliocco, MA; Pandya, K; Wong, Y	1
Berger, V; Breneman, D; Naini, V; Sheth, P; Stevens, V	1

Trials

5 trial(s) available for bexarotene and Psoriasis

Article	Year
A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion. The British journal of dermatology, 2003, Volume: 149, Issue:3 Topics: Adult; Aged; Bexarotene; Cell Differentiation; Cell Division; Dermatologic Agents; Epidermis; Female; Flow Cytometry; Humans; Keratinocytes; Male; Middle Aged; Psoriasis; Tetrahydronaphthalenes; Vimentin	2003
Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:2 Topics: Administration, Oral; Adult; Apoptosis; Bexarotene; Biopsy, Needle; Cell Differentiation; Dermatitis; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidermis; Humans; Immunohistochemistry; Keratinocytes; Ki-67 Antigen; Psoriasis; Tetrahydronaphthalenes	2004
A phase II multicenter clinical trial of systemic bexarotene in psoriasis. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:2 Topics: Adult; Bexarotene; CD4 Antigens; Female; Humans; Hypertriglyceridemia; Male; Psoriasis; Quality of Life; Secondary Prevention; Tetrahydronaphthalenes; Treatment Outcome	2004
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. Journal of the American Academy of Dermatology, 2006, Volume: 54, Issue:1 Topics: Administration, Topical; Adult; Aged; Bexarotene; Double-Blind Method; Drug Administration Schedule; Female; Gels; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Retinoids; Severity of Illness Index; Tetrahydronaphthalenes; Treatment Outcome; Ultraviolet Therapy	2006
Phase II clinical trial of bexarotene gel 1% in psoriasis. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Bexarotene; Dermatologic Agents; Drug Administration Schedule; Female; Gels; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Skin; Surveys and Questionnaires; Tetrahydronaphthalenes; Treatment Outcome	2007

Other Studies

1 other study(ies) available for bexarotene and Psoriasis

Article	Year
Design, synthesis and characterization of a novel multicomponent salt of bexarotene with metformin and application in ameliorating psoriasis with T2DM. International journal of pharmaceutics, 2023, Nov-05, Volume: 646 Topics: Animals; Bexarotene; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Imiquimod; Metformin; Mice; Psoriasis; Sodium Chloride; Tetrahydronaphthalenes	2023